about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Chi­na opens the door for biotech in­vestors in Hong Kong to buy Shang­hai stocks, and vice ver­sa

5 years ago
Financing
China

Urovan­t's lead drug dis­ap­points in mid-stage study as first big FDA de­ci­sion looms

5 years ago
R&D

Covid-19 roundup: Eu­rope pur­chas­es 80M dos­es of Mod­er­na's vac­cine; CO­V­AXX se­cures $2.8B in emerg­ing mar­ket pre-or­ders

5 years ago
Coronavirus

PhRMA sues Trump gov­ern­ment over drug im­por­ta­tion rule — days be­fore it's set to be ef­fec­tive

5 years ago
Pharma

Covid-19 roundup: Rus­sia prices vac­cine 't­wo or more times cheap­er' than mR­NA shots; Sino­vac PhI­II da­ta ex­pect­ed in ...

5 years ago
Coronavirus

News brief­ing: Ab­b­Vie part­ner Teneo­bio ex­pands tech li­cense with CAR-T play­er Po­sei­da; Ar­genx buys PRV from Bay­er for ...

5 years ago
News Briefing

Plot thick­ens around Leg­end Biotech, Gen­Script with founder Frank Zhang's ar­rest

5 years ago
People
China

As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

5 years ago
Coronavirus

As­traZeneca, Sam­sung quit race to de­vel­op Rit­ux­an copy­cat as ri­vals crowd out the mar­ket

5 years ago
Deals

Covid-19 roundup: WHO rec­om­mends against 'high cost' remde­sivir, dis­ap­point­ing Gilead; EU deals with Pfiz­er/BioN­Tech, ...

5 years ago
Coronavirus

Covid-19 roundup: J&J en­ters PhI­II with a two-dose reg­i­men to play safe; As­traZeneca, Ox­ford tout promis­ing da­ta in ...

5 years ago
Coronavirus

Pfiz­er hands Lian­Bio $70M to tag along Per­cep­tive's Chi­na play, with an eye to beef­ing up re­gion­al port­fo­lio

5 years ago
Deals
China

Amid scruti­ny of ex­ec stock sales, SEC chair­man echoes calls for 'cool­ing-off pe­ri­od' in trad­ing plans

5 years ago
People
FDA+

News brief­ing: Pfiz­er and Vivet get the OK to start gene ther­a­py tri­al for rare liv­er dis­or­der; Flori­da biotech inks ...

5 years ago
News Briefing

Ko­re­a's Cell­tri­on in­vests $453M in­to new man­u­fac­tur­ing plant, re­search cen­ter

5 years ago
Outsourcing
Manufacturing

MPM, DCVC Bio back $53M round for a bold con­cept: Let pa­tients make their own CAR-T in vi­vo

5 years ago
Financing
Startups

Bio­Marin taps AI up­start Deep Ge­nomics for dis­cov­ery pact; Prax­is says it has a path to lift­ing clin­i­cal hold

5 years ago
News Briefing

Here's a $200M Chi­na start­up idea — if you can read be­yond the big words

5 years ago
Financing
Startups

With a 'monopoly' on gly­co­pro­teomics, In­ter­Venn rais­es $34M to push can­cer di­ag­nos­tic in­to the clin­ic, woos Il­lu­mi­na ...

5 years ago
Financing

News brief­ing: Gilead, No­vo of­fer first glimpse at NASH cock­tail da­ta; Sean Bo­hen's can­cer biotech sets terms for ...

5 years ago
News Briefing

Covid-19 roundup: In­ovio fi­nal­ly gets PhII rolling — but there's still a clin­i­cal hold; Low cost vac­cine en­ters ...

5 years ago
Coronavirus

Sanofi grap­ples with re­jec­tion of po­ten­tial first-in-class or­phan drug, faults third-par­ty man­u­fac­tur­ing

5 years ago
FDA+

Short­age of mon­keys slowed down Eli Lil­ly's Covid-19 an­ti­body part­ner. And it's a prob­lem for every­one

5 years ago
R&D
China

Covid-19 roundup: J&J part­ners with Unit­ed­Health to hit the gas on vac­cine tri­al en­roll­ment; BioN­Tech CEO Ugur Sahin ...

5 years ago
Coronavirus
First page Previous page 61626364656667 Next page Last page
A service from the Financial Times